AstraZeneca drug Fasenra fails to achieve main goal in COPD trial
May 30 (Reuters) - AstraZeneca (NYSE: AZN - news) 's first respiratory biological medicine Fasenra failed to meet its main target in a second clinical trial treating patients with moderate to very severe chronic obstructive pulmonary disease (COPD).
The drug is currently approved as an add-on treatment for severe eosinophilic asthma in the United States, the European Union, Japan and several other countries.
Fasenra failed to meet its target in the final-stage trial, named Galathea, this month.
(Reporting By Justin George Varghese in Bengaluru Editing by David Goodman)